Active, not recruitingPhase 2NCT02581930
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma
Studying Neuroendocrine neoplasm
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Stergios J MoschosDuke University - Duke Cancer Institute LAO
- Intervention
- Ibrutinib(drug)
- Enrollment
- 18 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2016 – 2027
Study locations (13)
- Los Angeles General Medical Center, Los Angeles, California, United States
- USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
- University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
- UCHealth University of Colorado Hospital, Aurora, Colorado, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
- Duke University Medical Center, Durham, North Carolina, United States
- Case Western Reserve University, Cleveland, Ohio, United States
- Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
- University of Virginia Cancer Center, Charlottesville, Virginia, United States
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02581930 on ClinicalTrials.govOther trials for Neuroendocrine neoplasm
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06406465A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and ToxicityNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06202066Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine CarcinomasRoswell Park Cancer Institute
- RECRUITINGPHASE1NCT07224425A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it HelpsBoehringer Ingelheim
- RECRUITINGPHASE2NCT07449754Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant MelanomaHanmi Pharmaceutical Company Limited
- RECRUITINGPHASE2NCT07336147Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical CarcinomaChang Gung Memorial Hospital
- RECRUITINGPHASE1NCT07086105A Study to Evaluate Adze1.C in Participants With Metastatic MelanomaAdze Biotechnology Australia Pty Ltd
- RECRUITINGPHASE2NCT07357623Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine TumorsShanghai Chest Hospital
- RECRUITINGPHASE2NCT07215182[68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in CancerBarbara Malene Fischer